Kopran Limited has responded to multiple inquiries from the Bombay Stock Exchange (BSE) regarding unusual trading patterns in the company's scrip. The pharmaceutical company has clarified that recent increases in both trading volumes and share price are purely market-driven, with no undisclosed material information influencing the movements.

Dual BSE Surveillance Inquiries

The BSE surveillance department has made two separate inquiries to Kopran Limited within a span of two days. The first inquiry, referenced L/SURV/ONL/PV/SG/2026-2027/17, addressed significant volume movement across exchanges. The second inquiry, referenced L/SURV/ONL/PV/APJ/2026-2027/3666, focused on significant price movement in the scrip.

Company's Consistent Response

In both responses, Kopran Limited maintained a consistent position regarding regulatory compliance. The company emphasized that it has made all required disclosures in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

The pharmaceutical company confirmed that it has not withheld any material information or events that could have a bearing on either the volume increase or price movement in its scrip. Both the volume surge and price appreciation have been attributed to market forces rather than any specific corporate developments.

Regulatory Compliance Framework

Under SEBI regulations, listed companies are required to disclose any material events or information that could impact their stock price or trading volumes. Kopran's responses indicate full compliance with these disclosure requirements, suggesting that the trading activity is driven by market sentiment rather than undisclosed corporate information.

Official Documentation

Both responses were signed by Sunil Sodhani, Company Secretary and Compliance Officer (Membership No. FCS 3897). The April 10 response was digitally signed, ensuring the authenticity and official nature of the communication. The company maintains its registered office at Parijat House, Dr. E. Moses Road, Worli, Mumbai, with manufacturing facilities in Raigad district.

Kopran Limited has filed its quarterly compliance certificate with securities depositories, confirming adherence to SEBI regulations governing dematerialization processes for the quarter ended March 31, 2026.

Regulatory Compliance Certification

The pharmaceutical company submitted its certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 to both National Securities Depository Limited and Central Depository Services (India) Limited on April 09, 2026. Company Secretary and Compliance Officer Sunil Sodhani signed the certification document.

Registrar Confirmation

Bigshare Services Pvt. Ltd., serving as Kopran's registrar and share transfer agent, provided supporting documentation for the compliance certificate dated April 08, 2026. The registrar confirmed that securities received from depository participants for dematerialization up to March 31, 2026 were properly processed and confirmed to the depositories.

The registrar's certificate, signed by authorized signatory Akash Shamal, verified that:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities were properly listed on stock exchanges where existing securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Filing Details

The compliance documentation was simultaneously submitted to stock exchanges where Kopran's shares are listed. The company maintains its listing on both BSE Limited and National Stock Exchange of India Limited.

This quarterly filing represents part of Kopran's ongoing regulatory compliance obligations as a publicly listed pharmaceutical company, ensuring proper handling of dematerialized securities and maintaining transparency with market regulators and depositories.